🔗 Share this article

Given that the US continues making historic adjustments to its immunization recommendations, a particular individual has surfaced unexpectedly: Tracy Beth Høeg, a US-based sports physician and epidemiologist who rose to prominence by questioning Covid vaccines in the global health crisis and has zeroed in on alleged deaths after Covid immunization in her brief tenure at the Food and Drug Administration.

Scheduled Shifts to Pediatric Vaccine Schedule

Public health authorities planned to reveal sweeping changes to the pediatric immunization program earlier this month, synchronizing the US with Denmark’s national calendar, sources say – a significant shift that would place the US out of step with a large portion of the international standard with no evidence for improved outcomes. This reveal has been postponed until the coming year.

Rather than the director of the vaccine center, Høeg is set to speak at the event. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the center this year.

A Shift at the FDA

Høeg's temporary position might represent a tighter collaboration between the drug and biologics divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it signals a increased emphasis upon reevaluating long-standing vaccines at the FDA.

Dr. Høeg has repeatedly called for halting some pediatric vaccine recommendations in the US in order to be more like the Danish model, a society with nationalized medicine and a citizenry about the population of Wisconsin’s.

To date comments, she has persisted in emphasizing on immunizations – traditionally the responsibility of Prasad, director of the FDA’s CBER – as opposed to medication approval.

Questions Over Expertise

Dr. Høeg has little discernible track record in drug development, regulation or administrative roles, which has been customary for past directors of the biologics center. She has served at the FDA as a top consultant to the agency head and CBER since March.

“She appears not to have any of the qualifications” for running the CDER, said Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in leading a major agency. She lacks background in industry regulation.”

Previous heads of CBER would “be deeply familiar with regulatory frameworks and the science of pharmaceutical innovation”, said a former acting FDA commissioner. “Objectively, she doesn’t have the sort of resume that former directors who headed the center have had.”

CDER has an vast range of responsibilities at the FDA, Woodcock pointed out.

“Many people just focuses on the new drug program, but the generic program authorizes thousands of off-brand pharmaceuticals. There’s a biologic copycat branch, over-the-counter program and other areas, and all of those must be looked after,” Woodcock explained. “The thing you overlook, that is precisely what that I always told people is going to bite you.”

There is also, a significant leadership component to the job, which manages over 5,000 employees. “It’s a enormous leadership role, if you execute it properly,” Woodcock said.

Agency Reaction and Disputed Initiatives

When asked about inquiries about Høeg’s fitness for the role and whether this selection signifies increased cooperation among regulatory chiefs on immunizations, a representative stated that the “inquiries rely on inaccurate presumptions”.

“Her experience aligns with the responsibilities of her job,” the spokesperson explained, citing the months Høeg spent advising the FDA commissioner on “drug safety and regulatory science, including computational safety modeling and shot safety tracking”.

As acting director, Dr. Høeg assumes responsibility for the commissioner’s recently launched fast-track approval initiative, a disputed rapid medication authorization process that reportedly troubled her former heads. “By what process are these therapies being selected for this voucher program? Who makes the calls?” Dr. Howard questioned. “There’s a lot of secrecy happening at the agency right now.”

Broadly speaking, he said, “the Food and Drug Administration appears to be shifting towards laxer rules of pharmaceuticals, aside from immunizations.”

Public Past Work on Vaccines

Concerning vaccines, Høeg has a more documented, if concerning, past, critics observe. She authored a research paper using unverified public submissions to estimate the rate of myocarditis following COVID-19 vaccination. She advised the state of Florida surgeon general Joseph Ladapo, who allegedly have changed statistics to imply Covid vaccines are pose a greater threat than they are.

Among her “wish list” for the current administration included revising regulations for novel immunizations and ending “non-essential” vaccines, she said post-election on a audio program. At the agency, Dr. Høeg has reportedly suggested excluding teenage boys from obtaining Covid vaccinations.

“She is an complete dogmatist who starts off with her conclusions and tailors the evidence to accommodate the science in a highly misleading, dishonest manner,” Dr. Howard stated.

Consolidating Power and a “Push for Payback”

Dr. Høeg joined other skeptics, {like|